Share Price and Basic Stock Data
Last Updated: March 7, 2025, 2:41 pm
PEG Ratio | 2.85 |
---|
Competitors of Glaxosmithkline Pharmaceuticals Ltd
Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
---|---|---|---|---|---|---|---|---|---|
MPS Pharmaa Ltd | 7.05 Cr. | 3.69 | 4.33/3.05 | 0.80 | 0.00 % | 9.15 % | 34.9 % | 10.0 | |
Gujarat Themis Biosyn Ltd | 2,663 Cr. | 244 | 390/192 | 50.6 | 20.5 | 0.27 % | 45.0 % | 33.8 % | 1.00 |
Gujarat Terce Laboratories Ltd | 51.9 Cr. | 70.0 | 94.9/32.1 | 17.6 | 11.9 | 0.00 % | 9.72 % | 3.44 % | 10.0 |
Gujarat Inject (Kerala) Ltd | 39.6 Cr. | 27.0 | 29.0/8.74 | 40.4 | 6.64 | 0.00 % | 2.65 % | 2.08 % | 10.0 |
Godavari Drugs Ltd | 76.2 Cr. | 101 | 155/79.0 | 12.3 | 55.4 | 0.00 % | 14.4 % | 15.5 % | 10.0 |
Industry Average | 17,498.14 Cr | 1,090.41 | 42.74 | 185.80 | 0.36% | 16.00% | 16.32% | 6.27 |
All Competitor Stocks of Glaxosmithkline Pharmaceuticals Ltd
Quarterly Result
Metric | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales | 816 | 810 | 745 | 917 | 802 | 787 | 762 | 957 | 805 | 930 | 815 | 1,011 | 949 |
Expenses | 618 | 634 | 596 | 660 | 574 | 618 | 618 | 668 | 587 | 673 | 584 | 689 | 658 |
Operating Profit | 198 | 175 | 149 | 257 | 229 | 170 | 144 | 289 | 218 | 257 | 231 | 322 | 292 |
OPM % | 24% | 22% | 20% | 28% | 29% | 22% | 19% | 30% | 27% | 28% | 28% | 32% | 31% |
Other Income | 4 | 1,322 | 31 | 22 | 12 | 38 | 54 | 28 | -135 | 32 | 36 | 39 | 35 |
Interest | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
Depreciation | 18 | 15 | 16 | 16 | 16 | 17 | 16 | 18 | 17 | 18 | 16 | 17 | 19 |
Profit before tax | 184 | 1,482 | 163 | 262 | 224 | 190 | 181 | 299 | 65 | 271 | 249 | 344 | 308 |
Tax % | 18% | 18% | 27% | 26% | 27% | 30% | 27% | 27% | 30% | 28% | 27% | 27% | 25% |
Net Profit | 150 | 1,219 | 119 | 193 | 165 | 133 | 132 | 218 | 46 | 194 | 182 | 252 | 230 |
EPS in Rs | 8.88 | 71.96 | 7.04 | 11.42 | 9.71 | 7.88 | 7.81 | 12.84 | 2.70 | 11.48 | 10.76 | 14.91 | 13.57 |
Last Updated: February 28, 2025, 7:50 pm
Below is a detailed analysis of the quarterly data for Glaxosmithkline Pharmaceuticals Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:
- For Sales, as of Dec 2024, the value is ₹949.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,011.00 Cr. (Sep 2024) to ₹949.00 Cr., marking a decrease of 62.00 Cr..
- For Expenses, as of Dec 2024, the value is ₹658.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 689.00 Cr. (Sep 2024) to ₹658.00 Cr., marking a decrease of 31.00 Cr..
- For Operating Profit, as of Dec 2024, the value is ₹292.00 Cr.. The value appears to be declining and may need further review. It has decreased from 322.00 Cr. (Sep 2024) to ₹292.00 Cr., marking a decrease of 30.00 Cr..
- For OPM %, as of Dec 2024, the value is 31.00%. The value appears to be declining and may need further review. It has decreased from 32.00% (Sep 2024) to 31.00%, marking a decrease of 1.00%.
- For Other Income, as of Dec 2024, the value is ₹35.00 Cr.. The value appears to be declining and may need further review. It has decreased from 39.00 Cr. (Sep 2024) to ₹35.00 Cr., marking a decrease of 4.00 Cr..
- For Interest, as of Dec 2024, the value is ₹0.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 0.00 Cr..
- For Depreciation, as of Dec 2024, the value is ₹19.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 17.00 Cr. (Sep 2024) to ₹19.00 Cr., marking an increase of ₹2.00 Cr..
- For Profit before tax, as of Dec 2024, the value is ₹308.00 Cr.. The value appears to be declining and may need further review. It has decreased from 344.00 Cr. (Sep 2024) to ₹308.00 Cr., marking a decrease of 36.00 Cr..
- For Tax %, as of Dec 2024, the value is 25.00%. The value appears to be improving (decreasing) as expected. It has decreased from 27.00% (Sep 2024) to 25.00%, marking a decrease of 2.00%.
- For Net Profit, as of Dec 2024, the value is ₹230.00 Cr.. The value appears to be declining and may need further review. It has decreased from 252.00 Cr. (Sep 2024) to ₹230.00 Cr., marking a decrease of 22.00 Cr..
- For EPS in Rs, as of Dec 2024, the value is 13.57. The value appears to be declining and may need further review. It has decreased from ₹14.91 (Sep 2024) to 13.57, marking a decrease of ₹1.34.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: March 6, 2025, 4:13 pm
Metric | Dec 2012 | Dec 2013 | Mar 2015n n 15m | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales | 2,647 | 2,563 | 3,305 | 2,838 | 2,908 | 2,871 | 3,128 | 3,224 | 2,926 | 3,278 | 3,252 | 3,454 | 3,705 |
Expenses | 1,824 | 2,034 | 2,672 | 2,360 | 2,489 | 2,363 | 2,527 | 2,567 | 2,327 | 2,516 | 2,447 | 2,545 | 2,603 |
Operating Profit | 822 | 528 | 633 | 478 | 420 | 508 | 601 | 657 | 598 | 762 | 804 | 909 | 1,101 |
OPM % | 31% | 21% | 19% | 17% | 14% | 18% | 19% | 20% | 20% | 23% | 25% | 26% | 30% |
Other Income | 30 | 203 | 149 | 125 | 119 | 70 | 131 | -262 | 9 | 1,401 | 103 | -21 | 142 |
Interest | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 6 | 4 | 2 | 2 | 2 | 2 |
Depreciation | 18 | 20 | 25 | 25 | 27 | 38 | 49 | 83 | 79 | 68 | 66 | 70 | 70 |
Profit before tax | 834 | 711 | 756 | 578 | 511 | 540 | 683 | 306 | 525 | 2,093 | 839 | 816 | 1,172 |
Tax % | 33% | 32% | 37% | 35% | 34% | 35% | 35% | 70% | 32% | 19% | 27% | 28% | |
Net Profit | 562 | 482 | 476 | 376 | 337 | 351 | 445 | 93 | 358 | 1,695 | 611 | 590 | 859 |
EPS in Rs | 33.17 | 28.43 | 28.12 | 22.20 | 19.88 | 20.70 | 26.29 | 5.50 | 21.14 | 100.04 | 36.05 | 34.83 | 50.72 |
Dividend Payout % | 75% | 88% | 111% | 113% | 75% | 85% | 76% | 727% | 142% | 90% | 89% | 92% |
YoY Net Profit Growth
Year | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 |
---|---|---|---|---|---|---|---|---|
YoY Net Profit Growth (%) | -10.37% | 4.15% | 26.78% | -79.10% | 284.95% | 373.46% | -63.95% | -3.44% |
Change in YoY Net Profit Growth (%) | 0.00% | 14.53% | 22.63% | -105.88% | 364.05% | 88.52% | -437.42% | 60.52% |
Glaxosmithkline Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 8 years from 2016-2017 to 2023-2024.
Growth
Compounded Sales Growth | |
---|---|
10 Years: | 3% |
5 Years: | 2% |
3 Years: | 6% |
TTM: | 12% |
Compounded Profit Growth | |
---|---|
10 Years: | 4% |
5 Years: | 9% |
3 Years: | 11% |
TTM: | 33% |
Stock Price CAGR | |
---|---|
10 Years: | 5% |
5 Years: | 16% |
3 Years: | 21% |
1 Year: | 34% |
Return on Equity | |
---|---|
10 Years: | 28% |
5 Years: | 37% |
3 Years: | 49% |
Last Year: | 37% |
Last Updated: Unknown
Balance Sheet
Last Updated: November 14, 2024, 11:41 pm
Month | Dec 2012 | Dec 2013 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 85 | 85 | 85 | 85 | 85 | 85 | 169 | 169 | 169 | 169 | 169 | 169 | 169 |
Reserves | 1,922 | 1,905 | 1,744 | 2,099 | 1,922 | 1,973 | 1,970 | 1,651 | 1,309 | 2,494 | 1,572 | 1,608 | 1,503 |
Borrowings | 5 | 4 | 3 | 2 | 2 | 1 | 1 | 0 | 35 | 20 | 16 | 19 | 15 |
Other Liabilities | 1,077 | 1,136 | 1,384 | 869 | 995 | 1,889 | 1,771 | 1,312 | 1,602 | 1,950 | 1,570 | 1,760 | 2,059 |
Total Liabilities | 3,088 | 3,130 | 3,216 | 3,055 | 3,004 | 3,947 | 3,911 | 3,133 | 3,115 | 4,633 | 3,327 | 3,557 | 3,746 |
Fixed Assets | 89 | 100 | 123 | 204 | 258 | 325 | 432 | 758 | 387 | 331 | 330 | 321 | 296 |
CWIP | 44 | 62 | 115 | 268 | 605 | 923 | 1,003 | 120 | 13 | 30 | 20 | 14 | 21 |
Investments | 55 | 10 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 366 | 518 | 813 | 1,001 |
Other Assets | 2,900 | 2,958 | 2,977 | 2,577 | 2,140 | 2,700 | 2,477 | 2,255 | 2,715 | 3,907 | 2,458 | 2,408 | 2,428 |
Total Assets | 3,088 | 3,130 | 3,216 | 3,055 | 3,004 | 3,947 | 3,911 | 3,133 | 3,115 | 4,633 | 3,327 | 3,557 | 3,746 |
Below is a detailed analysis of the balance sheet data for Glaxosmithkline Pharmaceuticals Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2024, the value is ₹169.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹169.00 Cr..
- For Reserves, as of Sep 2024, the value is ₹1,503.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹1,608.00 Cr. (Mar 2024) to ₹1,503.00 Cr., marking a decrease of 105.00 Cr..
- For Borrowings, as of Sep 2024, the value is ₹15.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from ₹19.00 Cr. (Mar 2024) to ₹15.00 Cr., marking a decrease of 4.00 Cr..
- For Other Liabilities, as of Sep 2024, the value is ₹2,059.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹1,760.00 Cr. (Mar 2024) to ₹2,059.00 Cr., marking an increase of 299.00 Cr..
- For Total Liabilities, as of Sep 2024, the value is ₹3,746.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹3,557.00 Cr. (Mar 2024) to ₹3,746.00 Cr., marking an increase of 189.00 Cr..
- For Fixed Assets, as of Sep 2024, the value is ₹296.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹321.00 Cr. (Mar 2024) to ₹296.00 Cr., marking a decrease of 25.00 Cr..
- For CWIP, as of Sep 2024, the value is ₹21.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹14.00 Cr. (Mar 2024) to ₹21.00 Cr., marking an increase of 7.00 Cr..
- For Investments, as of Sep 2024, the value is ₹1,001.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹813.00 Cr. (Mar 2024) to ₹1,001.00 Cr., marking an increase of 188.00 Cr..
- For Other Assets, as of Sep 2024, the value is ₹2,428.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹2,408.00 Cr. (Mar 2024) to ₹2,428.00 Cr., marking an increase of 20.00 Cr..
- For Total Assets, as of Sep 2024, the value is ₹3,746.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹3,557.00 Cr. (Mar 2024) to ₹3,746.00 Cr., marking an increase of 189.00 Cr..
Notably, the Reserves (₹1,503.00 Cr.) exceed the Borrowings (15.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
Month | Dec 2012 | Dec 2013 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
Month | Dec 2012 | Dec 2013 | Mar 2015n n 15m | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow | 817.00 | 524.00 | 633.00 | 476.00 | 418.00 | 507.00 | 600.00 | 657.00 | 563.00 | 742.00 | 788.00 | 890.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
Month | Dec 2012 | Dec 2013 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 16 | 14 | 11 | 16 | 21 | 19 | 14 | 11 | 27 | 23 | 22 | 23 |
Inventory Days | 94 | 109 | 91 | 156 | 111 | 147 | 131 | 135 | 159 | 144 | 131 | 144 |
Days Payable | 78 | 90 | 74 | 97 | 73 | 149 | 109 | 100 | 135 | 156 | 122 | 171 |
Cash Conversion Cycle | 32 | 33 | 27 | 75 | 60 | 17 | 36 | 46 | 50 | 11 | 31 | -4 |
Working Capital Days | -42 | -45 | -48 | 26 | 7 | -90 | -72 | -38 | -37 | -92 | -55 | -62 |
ROCE % | 50% | 34% | 42% | 29% | 22% | 26% | 31% | 33% | 38% | 37% | 36% | 51% |
Mutual Fund Holdings
Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
---|---|---|---|---|---|---|
Aditya Birla Sun Life ELSS Tax Saver Fund | 1,218,872 | 1.42 | 201.98 | 1,218,872 | 2025-03-06 | 0% |
Nippon India Pharma Fund | 853,907 | 2.28 | 141.5 | 1,218,872 | 2025-03-06 | -29.94% |
ICICI Prudential Large & Mid Cap Fund | 839,179 | 1.44 | 139.06 | 1,218,872 | 2025-03-06 | -31.15% |
SBI Magnum Midcap Fund | 806,895 | 0.93 | 133.71 | 1,218,872 | 2025-03-06 | -33.8% |
Aditya Birla Sun Life MNC Fund - Div | 753,600 | 3.58 | 124.88 | 1,218,872 | 2025-03-06 | -38.17% |
Aditya Birla Sun Life MNC Fund - Gr | 753,600 | 3.58 | 124.88 | 1,218,872 | 2025-03-06 | -38.17% |
ICICI Prudential Multi Asset Fund | 753,257 | 0.45 | 124.82 | 1,218,872 | 2025-03-06 | -38.2% |
Nippon India Growth Fund | 559,000 | 0.43 | 92.63 | 1,218,872 | 2025-03-06 | -54.14% |
ICICI Prudential Value Discovery Fund | 355,184 | 0.17 | 58.86 | 1,218,872 | 2025-03-06 | -70.86% |
ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund | 293,814 | 1.48 | 48.69 | 1,218,872 | 2025-03-06 | -75.89% |
Key Financial Ratios
Month | Mar 24 | Mar 23 | Mar 22 | Mar 21 | Mar 20 |
---|---|---|---|---|---|
FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
Basic EPS (Rs.) | 41.14 | 36.08 | 99.29 | 31.35 | 5.50 |
Diluted EPS (Rs.) | 34.83 | 36.05 | 100.04 | 21.14 | 5.50 |
Cash EPS (Rs.) | 38.94 | 39.93 | 104.06 | 25.78 | 10.38 |
Book Value[Excl.RevalReserv]/Share (Rs.) | 104.93 | 102.79 | 157.19 | 87.26 | 107.47 |
Book Value[Incl.RevalReserv]/Share (Rs.) | 104.93 | 102.79 | 157.19 | 87.26 | 107.47 |
Revenue From Operations / Share (Rs.) | 203.87 | 191.95 | 193.50 | 172.70 | 190.33 |
PBDIT / Share (Rs.) | 60.88 | 53.42 | 49.45 | 41.84 | 43.46 |
PBIT / Share (Rs.) | 56.76 | 49.54 | 45.42 | 37.20 | 38.58 |
PBT / Share (Rs.) | 48.18 | 49.37 | 45.99 | 26.80 | 18.05 |
Net Profit / Share (Rs.) | 34.83 | 36.05 | 100.04 | 21.14 | 5.50 |
NP After MI And SOA / Share (Rs.) | 35.07 | 36.41 | 100.04 | 21.14 | 5.50 |
PBDIT Margin (%) | 29.86 | 27.82 | 25.55 | 24.22 | 22.83 |
PBIT Margin (%) | 27.84 | 25.80 | 23.47 | 21.53 | 20.26 |
PBT Margin (%) | 23.63 | 25.72 | 23.76 | 15.51 | 9.48 |
Net Profit Margin (%) | 17.08 | 18.78 | 51.69 | 12.24 | 2.89 |
NP After MI And SOA Margin (%) | 17.20 | 18.96 | 51.69 | 12.24 | 2.89 |
Return on Networth / Equity (%) | 33.42 | 35.41 | 63.64 | 24.22 | 5.11 |
Return on Capital Employeed (%) | 47.33 | 41.95 | 26.21 | 35.80 | 30.95 |
Return On Assets (%) | 16.70 | 18.53 | 36.57 | 11.49 | 2.97 |
Asset Turnover Ratio (%) | 1.00 | 0.80 | 0.83 | 0.93 | 0.91 |
Current Ratio (X) | 1.84 | 1.88 | 2.18 | 1.63 | 1.74 |
Quick Ratio (X) | 1.49 | 1.53 | 1.87 | 1.22 | 1.26 |
Inventory Turnover Ratio (X) | 1.11 | 0.81 | 1.04 | 0.89 | 0.97 |
Dividend Payout Ratio (NP) (%) | 91.24 | 247.21 | 29.98 | 189.20 | 363.51 |
Dividend Payout Ratio (CP) (%) | 81.66 | 223.39 | 28.82 | 155.15 | 192.63 |
Earning Retention Ratio (%) | 8.76 | -147.21 | 70.02 | -89.20 | -263.51 |
Cash Earning Retention Ratio (%) | 18.34 | -123.39 | 71.18 | -55.15 | -92.63 |
Interest Coverage Ratio (X) | 573.35 | 499.36 | 419.65 | 200.69 | 116.21 |
Interest Coverage Ratio (Post Tax) (X) | 408.84 | 336.84 | 185.96 | 131.22 | 69.61 |
Enterprise Value (Cr.) | 31854.06 | 21275.97 | 25686.86 | 23243.30 | 20012.10 |
EV / Net Operating Revenue (X) | 9.22 | 6.54 | 7.84 | 7.94 | 6.21 |
EV / EBITDA (X) | 30.89 | 23.51 | 30.67 | 32.80 | 27.18 |
MarketCap / Net Operating Revenue (X) | 9.53 | 6.90 | 8.59 | 8.34 | 6.54 |
Retention Ratios (%) | 8.75 | -147.21 | 70.01 | -89.20 | -263.51 |
Price / BV (X) | 18.52 | 12.88 | 10.58 | 16.51 | 11.59 |
Price / Net Operating Revenue (X) | 9.53 | 6.90 | 8.59 | 8.34 | 6.54 |
EarningsYield | 0.01 | 0.02 | 0.06 | 0.01 | 0.00 |
After reviewing the key financial ratios for Glaxosmithkline Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 24, the value is 41.14. This value is within the healthy range. It has increased from 36.08 (Mar 23) to 41.14, marking an increase of 5.06.
- For Diluted EPS (Rs.), as of Mar 24, the value is 34.83. This value is within the healthy range. It has decreased from 36.05 (Mar 23) to 34.83, marking a decrease of 1.22.
- For Cash EPS (Rs.), as of Mar 24, the value is 38.94. This value is within the healthy range. It has decreased from 39.93 (Mar 23) to 38.94, marking a decrease of 0.99.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 104.93. It has increased from 102.79 (Mar 23) to 104.93, marking an increase of 2.14.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 104.93. It has increased from 102.79 (Mar 23) to 104.93, marking an increase of 2.14.
- For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 203.87. It has increased from 191.95 (Mar 23) to 203.87, marking an increase of 11.92.
- For PBDIT / Share (Rs.), as of Mar 24, the value is 60.88. This value is within the healthy range. It has increased from 53.42 (Mar 23) to 60.88, marking an increase of 7.46.
- For PBIT / Share (Rs.), as of Mar 24, the value is 56.76. This value is within the healthy range. It has increased from 49.54 (Mar 23) to 56.76, marking an increase of 7.22.
- For PBT / Share (Rs.), as of Mar 24, the value is 48.18. This value is within the healthy range. It has decreased from 49.37 (Mar 23) to 48.18, marking a decrease of 1.19.
- For Net Profit / Share (Rs.), as of Mar 24, the value is 34.83. This value is within the healthy range. It has decreased from 36.05 (Mar 23) to 34.83, marking a decrease of 1.22.
- For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 35.07. This value is within the healthy range. It has decreased from 36.41 (Mar 23) to 35.07, marking a decrease of 1.34.
- For PBDIT Margin (%), as of Mar 24, the value is 29.86. This value is within the healthy range. It has increased from 27.82 (Mar 23) to 29.86, marking an increase of 2.04.
- For PBIT Margin (%), as of Mar 24, the value is 27.84. This value exceeds the healthy maximum of 20. It has increased from 25.80 (Mar 23) to 27.84, marking an increase of 2.04.
- For PBT Margin (%), as of Mar 24, the value is 23.63. This value is within the healthy range. It has decreased from 25.72 (Mar 23) to 23.63, marking a decrease of 2.09.
- For Net Profit Margin (%), as of Mar 24, the value is 17.08. This value exceeds the healthy maximum of 10. It has decreased from 18.78 (Mar 23) to 17.08, marking a decrease of 1.70.
- For NP After MI And SOA Margin (%), as of Mar 24, the value is 17.20. This value is within the healthy range. It has decreased from 18.96 (Mar 23) to 17.20, marking a decrease of 1.76.
- For Return on Networth / Equity (%), as of Mar 24, the value is 33.42. This value is within the healthy range. It has decreased from 35.41 (Mar 23) to 33.42, marking a decrease of 1.99.
- For Return on Capital Employeed (%), as of Mar 24, the value is 47.33. This value is within the healthy range. It has increased from 41.95 (Mar 23) to 47.33, marking an increase of 5.38.
- For Return On Assets (%), as of Mar 24, the value is 16.70. This value is within the healthy range. It has decreased from 18.53 (Mar 23) to 16.70, marking a decrease of 1.83.
- For Asset Turnover Ratio (%), as of Mar 24, the value is 1.00. It has increased from 0.80 (Mar 23) to 1.00, marking an increase of 0.20.
- For Current Ratio (X), as of Mar 24, the value is 1.84. This value is within the healthy range. It has decreased from 1.88 (Mar 23) to 1.84, marking a decrease of 0.04.
- For Quick Ratio (X), as of Mar 24, the value is 1.49. This value is within the healthy range. It has decreased from 1.53 (Mar 23) to 1.49, marking a decrease of 0.04.
- For Inventory Turnover Ratio (X), as of Mar 24, the value is 1.11. This value is below the healthy minimum of 4. It has increased from 0.81 (Mar 23) to 1.11, marking an increase of 0.30.
- For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 91.24. This value exceeds the healthy maximum of 50. It has decreased from 247.21 (Mar 23) to 91.24, marking a decrease of 155.97.
- For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 81.66. This value exceeds the healthy maximum of 50. It has decreased from 223.39 (Mar 23) to 81.66, marking a decrease of 141.73.
- For Earning Retention Ratio (%), as of Mar 24, the value is 8.76. This value is below the healthy minimum of 40. It has increased from -147.21 (Mar 23) to 8.76, marking an increase of 155.97.
- For Cash Earning Retention Ratio (%), as of Mar 24, the value is 18.34. This value is below the healthy minimum of 40. It has increased from -123.39 (Mar 23) to 18.34, marking an increase of 141.73.
- For Interest Coverage Ratio (X), as of Mar 24, the value is 573.35. This value is within the healthy range. It has increased from 499.36 (Mar 23) to 573.35, marking an increase of 73.99.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 408.84. This value is within the healthy range. It has increased from 336.84 (Mar 23) to 408.84, marking an increase of 72.00.
- For Enterprise Value (Cr.), as of Mar 24, the value is 31,854.06. It has increased from 21,275.97 (Mar 23) to 31,854.06, marking an increase of 10,578.09.
- For EV / Net Operating Revenue (X), as of Mar 24, the value is 9.22. This value exceeds the healthy maximum of 3. It has increased from 6.54 (Mar 23) to 9.22, marking an increase of 2.68.
- For EV / EBITDA (X), as of Mar 24, the value is 30.89. This value exceeds the healthy maximum of 15. It has increased from 23.51 (Mar 23) to 30.89, marking an increase of 7.38.
- For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 9.53. This value exceeds the healthy maximum of 3. It has increased from 6.90 (Mar 23) to 9.53, marking an increase of 2.63.
- For Retention Ratios (%), as of Mar 24, the value is 8.75. This value is below the healthy minimum of 30. It has increased from -147.21 (Mar 23) to 8.75, marking an increase of 155.96.
- For Price / BV (X), as of Mar 24, the value is 18.52. This value exceeds the healthy maximum of 3. It has increased from 12.88 (Mar 23) to 18.52, marking an increase of 5.64.
- For Price / Net Operating Revenue (X), as of Mar 24, the value is 9.53. This value exceeds the healthy maximum of 3. It has increased from 6.90 (Mar 23) to 9.53, marking an increase of 2.63.
- For EarningsYield, as of Mar 24, the value is 0.01. This value is below the healthy minimum of 5. It has decreased from 0.02 (Mar 23) to 0.01, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Strength | Weakness |
---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Glaxosmithkline Pharmaceuticals Ltd:
- Net Profit Margin: 17.08%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 47.33% (Industry Average ROCE: 15.87%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 33.42% (Industry Average ROE: 15.78%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 408.84
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.49
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 54.6 (Industry average Stock P/E: 34.26)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 17.08%
About the Company - Qualitative Analysis
INDUSTRY | ADDRESS | CONTACT |
---|---|---|
Pharmaceuticals | GSK House, Dr. Annie Besant Road, Mumbai Maharashtra 400030 | in.investorquery@gsk.com http://www.gsk-india.com |
Management | |
---|---|
Name | Position Held |
Ms. R S Karnad | Chairperson |
Mr. B Akshikar | Managing Director |
Mr. J Chandy | WholeTime Director & CFO |
Mr. S Williams | Non Executive Director |
Mr. M Anand | Independent Director |
Dr.(Ms.) S Maheshwari | Independent Director |
Mr. A N Roy | Independent Director |
Mr. D Sundaram | Independent Director |
Mr. P V Bhide | Independent Director |
FAQ
What is the latest intrinsic value of Glaxosmithkline Pharmaceuticals Ltd?
The latest intrinsic value of Glaxosmithkline Pharmaceuticals Ltd as on 08 March 2025 is ₹1626.74, which is 40.82% lower than the current market price of 2,749.00, indicating the stock is overvalued by 40.82%. The intrinsic value of Glaxosmithkline Pharmaceuticals Ltd is calculated using PE ratio method. The stock has a market capitalization of ₹46,567 Cr. and recorded a high/low of ₹3,088/1,825 during the current fiscal year 2024-2025. As of Sep 2024, the company has reserves of ₹1,503 Cr and total liabilities of ₹3,746 Cr.
What is the Market Cap of Glaxosmithkline Pharmaceuticals Ltd?
The Market Cap of Glaxosmithkline Pharmaceuticals Ltd is 46,567 Cr..
What is the current Stock Price of Glaxosmithkline Pharmaceuticals Ltd as on 08 March 2025?
The current stock price of Glaxosmithkline Pharmaceuticals Ltd as on 08 March 2025 is ₹2,749.
What is the High / Low of Glaxosmithkline Pharmaceuticals Ltd stocks in FY 2024-2025?
In FY 2024-2025, the High / Low of Glaxosmithkline Pharmaceuticals Ltd stocks is ₹3,088/1,825.
What is the Stock P/E of Glaxosmithkline Pharmaceuticals Ltd?
The Stock P/E of Glaxosmithkline Pharmaceuticals Ltd is 54.6.
What is the Book Value of Glaxosmithkline Pharmaceuticals Ltd?
The Book Value of Glaxosmithkline Pharmaceuticals Ltd is 98.7.
What is the Dividend Yield of Glaxosmithkline Pharmaceuticals Ltd?
The Dividend Yield of Glaxosmithkline Pharmaceuticals Ltd is 1.16 %.
What is the ROCE of Glaxosmithkline Pharmaceuticals Ltd?
The ROCE of Glaxosmithkline Pharmaceuticals Ltd is 51.3 %.
What is the ROE of Glaxosmithkline Pharmaceuticals Ltd?
The ROE of Glaxosmithkline Pharmaceuticals Ltd is 37.3 %.
What is the Face Value of Glaxosmithkline Pharmaceuticals Ltd?
The Face Value of Glaxosmithkline Pharmaceuticals Ltd is 10.0.